# A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

> **NCT01650701** · PHASE3 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 1030 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab - CHOP
- **DRUG:** Rituximab - CVP
- **DRUG:** Rituximab - Bendamustine

## Key facts

- **NCT ID:** NCT01650701
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2017-05-31
- **Final completion:** 2024-04-30
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650701, "A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01650701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*